Hsbc Holdings PLC Buys Shares of 248,195 Enovis Corporation $ENOV

Hsbc Holdings PLC bought a new position in Enovis Corporation (NYSE:ENOV) in the second quarter, Holdings Channel reports. The institutional investor bought 248,195 shares of the company’s stock, valued at approximately $5,016,000.

Several other institutional investors have also modified their holdings of the stock. Arax Advisory Partners acquired a new position in shares of Enovis during the 4th quarter valued at about $29,000. Allworth Financial LP acquired a new stake in Enovis during the second quarter worth about $36,000. EverSource Wealth Advisors LLC increased its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the last quarter. Danske Bank A S purchased a new position in Enovis during the third quarter worth about $64,000. Finally, iSAM Funds UK Ltd acquired a new position in Enovis in the 3rd quarter valued at about $80,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Insider Transactions at Enovis

In other Enovis news, insider Oliver Engert purchased 1,200 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the acquisition, the insider directly owned 51,840 shares of the company’s stock, valued at $1,120,780.80. This trade represents a 2.37% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders purchased 4,200 shares of company stock valued at $92,084 over the last three months. Corporate insiders own 2.90% of the company’s stock.

Enovis Stock Performance

Shares of Enovis stock opened at $24.91 on Friday. The business has a 50-day simple moving average of $25.60 and a 200-day simple moving average of $24.25. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. Enovis Corporation has a one year low of $19.14 and a one year high of $34.28. The company has a market cap of $1.44 billion, a PE ratio of -1.29 and a beta of 1.34.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.05. The firm had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm’s revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts forecast that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $30.00 price target on shares of Enovis in a research note on Friday, August 7th. Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Evercore set a $32.00 price target on shares of Enovis in a research note on Monday, July 6th. Wells Fargo & Company reduced their price target on shares of Enovis from $40.00 to $39.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Finally, Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $41.29.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.